Glycoprotein News and Research

RSS

Research paves way for improving efficacy of ALS treatement

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that primarily kills motor neurons, leading to paralysis and death 2 to 5 years from diagnosis. Currently ALS has no cure. Despite promising early-stage research, the majority of drugs in development for ALS have failed. Now researchers have uncovered a possible explanation.

23 Nov 2014

Research findings could pave way for new treatments against filoviruses

Filoviruses like Ebola "edit" genetic material as they invade their hosts, according to a study published this week in mBio, the online open-access journal of the American Society for Microbiology.

5 Nov 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

NanoBio to highlight prophylactic NE HSV-2 vaccine candidate at The Keystone Symposia Conference

NanoBio Corporation today announced that the company will present data at The Keystone Symposia Conference, The Modes of Action of Vaccine Adjuvants, in Seattle on October 12, 2014.

9 Oct 2014

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI) is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 today.

2 Sep 2014

Researchers develop potential antibody therapy for Sudan ebolavirus

Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola.

29 Aug 2014

Armetheon raises $7 million in first round of financing

Armetheon, Inc., a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing.

28 Aug 2014

Researchers compare benefits of bivalirudin and heparin for patients undergoing coronary stenting

Bivalirudin and heparin are two anticoagulant options for patients undergoing coronary stenting for ischemic heart disease. Bivalirudin, a newer anticoagulant, has been touted as being as effective as generic heparin, but with nearly half the rate of bleeding.

18 Aug 2014

Rice, Baylor scientists analyze how influenza-related proteins help infect cells

A flu virus acts like a Trojan horse as it attacks and infects host cells. Scientists at Rice University and Baylor College of Medicine have acquired a clearer view of the well-hidden mechanism involved.

1 Aug 2014

Phase II study reveals potential biomarker for HIV vaccine

Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.

18 Jul 2014

Research sheds new light on brain's complicated barrier tissue

Research from the University of Copenhagen is shedding new light on the brain's complicated barrier tissue. The blood-brain barrier is an effective barrier which protects the brain, but which at the same time makes it difficult to treat diseases such as Alzheimer's.

16 Jul 2014

Sugar-coated cells are potentially deadly for cancer patients

Every living cell's surface has a protein-embedded membrane that's covered in polysaccharide chains - a literal sugar coating. A new study by a Cornell University researcher found this coating is especially thick and pronounced on cancer cells and is a crucial determinant of the cell's survival.

2 Jul 2014

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

A recent study reported by Haigang Chang and co-workers from the First Affiliated Hospital of Xinxiang Medical University in China verified the effects of transient axonal glycoprotein-1 (TAG-1) on cell viability and p53, epidermal growth factor receptor (EGFR), and amyloid precursor protein (APP) intracellular C-terminal domain (AICD) expression in U251 glioma cells.

8 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Newly identified protein markers have potential to contribute to better understanding of heart disease

Researchers at the Intermountain Medical Center Heart Institute in Murray, Utah, have discovered that elevated levels of two recently identified proteins in the body are inflammatory markers and indicators of the presence of cardiovascular disease.

31 Mar 2014

Certain inherited DNA sequences may affect prognosis of bladder cancer patients

While patients diagnosed with bladder cancer usually face a favorable prognosis, many experience recurrence after treatment. Because frequent, painful screenings are needed to identify recurrences, the ablility to identify patients at high risk of recurrent cancer could help to improve quality of life for all bladder cancer patients.

29 Mar 2014

Patients with genetic variants are likely to experience bladder cancer recurrence

In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment.

26 Mar 2014

CLL patients more prone to infections due to reduced number of antibodies

People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes.

19 Mar 2014